Valproic acid enhances cisplatin cytotoxicity in melanoma cells

Acta Poloniae Pharmaceutica - Drug Research

Volumn 69, Issue 6, 2012, Pages 1298-1302

  Chodurek, Ewa ^a   Orchel, Arkadiusz ^a   Gruchlik, Arkadiusz ^a   Aleksander, Ewelina ^a   Goł̧abek, Karolina ^a   Dzierzewicz, Zofia ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cisplatin; Human melanoma cell lines; Proliferation; Valproic acid

Indexed keywords

CISPLATIN; CYTOSTATIC AGENT; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; MELANOMA CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; HUMANS; MELANOMA; VALPROIC ACID;

EID: 84870860334     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Palmieri G., Capone M., Ascierto M.L., Gentilcore G., Stroncek D.F., Casula M., Sini M.C., Palla M., Mozillo N., Ascierto P.A.: J. Transl. Med. 7, 86 (2009).
2. Riley P.A.: Pigment Cell Res. 16, 548 (2003).
3. Slominski A., Wortsman J., Nickoloff B., McClatchey K., Mihm M.C., Ross J.S.: Am. J. Clin. Pathol. 110, 788 (1998).
4. Nikolaou V.A., Stratigos A.J., Flaherty K.T., Tsao H.: J. Invest. Dermatol. 132, 854 (2012).
5. Tawbi H., Nimmagadda N.: Biologics 3, 475 (2009).
6. Schadendorf D., Algarra S.M., Bastholt L., Cinat G., Dreno B., Eggermont A.M.M., Espinosa E. et al.: Ann. Oncol. 20, 41 (2009).
7. Garbe C., Terheyden P., Keiholz U., Kölbl O., Hauschild A.: Dtsch. Arztebl. Int. 105, 845 (2008).
8. Burmeister B.H., Smithers M.B., Burmeister E., Baumann K., Davis S., Krawitz H., Johnson C., Spry N.: Radiother. Oncol. 81, 136 (2006).
9. Cepeda V., Fuertes M., Castilla J., Alonso C., Quevedo C., Perez J.: Anti-Cancer Agents Med. Chem. 7, 5 (2007).
10. Siddik Z H.: Oncogene 22, 7266 (2003).
11. Drewa T., Woźniak A., Olszewska D., Szłyk E., Lakomska I., Mila-Kierzenkowska C., Czajkowski R.: Acta Pol. Pharm. Drug Res. 58, 169 (2001).
12. Atkins M.B., Hsu J., Lee S., Cohen G.I., Flaherty L.E., Sosman J.A., Sondak V.K., Kirkwood J.M.; Eastern Cooperative Oncology Group.: J. Clin. Oncol. 26, 5748 (2008).
13. Helmbach H., Kern M.A., Rossmann E., Renz K., Kissel C., Gschwendt B., Schadendorf D.: J. Invest. Dermatol. 118, 923 (2002).
14. Güven K., Kittler H., Wolff K., Pehamberger H.: Melanoma Res., 11, 411 (2001).
15. Martinet N., Bertrand P.: Cancer Manag. Res. 3, 117 (2011).
16. Chateauvieux S., Morceau F., Dicato M., Diederich M.: .J. Biomed. Biotechnol. pii: 479364. Epub (2010).
17. Howell P.M. Jr., Liu S., Ren S., Behlen C., Fodstad O., Riker A.I.: Cancer Control. 16, 200 (2009).
18. Nolan L., Johnson P.W., Ganesan A., Packham G., Crabb S.J.: Br. J. Cancer 99, 689 (2008).
19. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., Cruz-Hernandez E., Herrera L.A.: Cancer Treat. Rev. 34, 208 (2008).
20. Rocca A., Minucci S., Tosti G., Croci D., Contegno F., Ballarini M., Nole F. et al.: Br. J. Cancer 100, 28 (2009).
21. Hanigan M.H., Devarajan P.: Cancer Ther. 1, 47 (2003).
22. Basu A., Krishnamurthy S.: J. Nucleic Acids Article ID 201367 (2010).
23. Valentini A., Gravina P., Federici G., Bernardini S.: Canc. Biol. Ther. 6, e2 (2007).
24. Erlich R.B., Rickwood D., Coman W.B., Saunders N.A., Guminski A.: Cancer Chemother. Pharmacol. 63, 381 (2009).